Anito-cel Yields Enduring Efficacy in Relapsed/Refractory Multiple Myeloma
Treatment with anito-cel shows a predictable and manageable safety profile among those with relapsed/refractory multiple myeloma in the iMMagine-1 trial.
Subcutaneous Daratumumab Provides “Win-Win” in NDMM Maintenance
Patients with high-risk markers may especially benefit from the addition of daratumumab to lenalidomide as maintenance therapy for NDMM.
Considering Subsequent Treatment in NDMM After Teclistamab-Based Induction
Marc S. Raab, MD, PhD, details how agents such as carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.
Dara-KRd Regimen Displays Prolonged PFS in Newly Diagnosed Multiple Myeloma
The median PFS was not reached with daratumumab-lenalidomide maintenance after a median follow-up of 49 months in those with multiple myeloma.
Isa-VRd Meets Primary End Point in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
The VGPR or better rate was 87.8% in patients treated with Isa-VRd who had transplant-ineligible newly diagnosed multiple myeloma.
Belantamab Exhibits Rapid/Prolonged Plasmablast Cell Reduction in Myeloma
No TRAEs leading to dose discontinuation, DLTs, or belantamab-related corneal events above grade 1 occurred with belantamab in multiple myeloma.
Sonrotoclax Combo Shows Safety, Promising Efficacy in R/R Multiple Myeloma
Phase 1b/2 BGB-11417-105 trial data showed low rates of high-grade infection and hematologic toxicity with sonrotoclax-based therapy in multiple myeloma.
Belantamab Mafodotin Triplet Highlights Low Ocular Toxicity in Intermediate-Fit, Frail Newly Diagnosed Myeloma
Belantamab mafodotin plus lenalidomide and dexamethasone yielded a stringent CR of 42.9% in patients with newly diagnosed multiple myeloma.
Daratumumab Quadruplet Improves Efficacy in Transplant-Ineligible or-Deferred, Newly Diagnosed Myeloma
Daratumumab, lenalidomide, ixazomib, and dexamethasone yielded PFS/OS outcomes in transplant-ineligible, newly diagnosed myeloma.
Iberdomide Combo Leads to Deepening Responses in Transplant-Ineligible NDMM
Iberdomide with daratumumab and dexamethasone led to an ORR of 93.1%, with stringent CRs in 30.1%, in those with newly diagnosed multiple myeloma.
Concurrent CAR T Product Infusion Appears Feasible in R/R Multiple Myeloma
Data from the TANDEMM trial show enduring responses with concurrent anti-GPRC5D and anti-BCMA therapy in relapsed/refractory multiple myeloma.
Eque-Cel Displays Favorable Long-Term Survival in R/R Multiple Myeloma
The long-term safety profile of equecabtagene autoleucel was manageable, with no new safety signals identified in those with multiple myeloma.
Arlo-Cel Yields Efficacy, Safety in Previously Treated R/R Multiple Myeloma
As a 1-time dose, arlo-cel yielded promising efficacy and safety for patients with previously treated relapsed/refractory multiple myeloma.
BPd Maintenance Safe, Yields Responses in High-Risk Multiple Myeloma
Patients with high-risk multiple myeloma who received BPd maintenance therapy reported no events of progression in the phase 2 trial.
Comorbidities May Influence Teclistamab Induction Regimen Use in NDMM
The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.
ISB 2001 Yields Durable Responses, Manageable Safety in R/R Multiple Myeloma
Treatment with ISB 2001 led to an overall response rate of 74% across dose levels 1 to 9 in patients with relapsed/refractory multiple myeloma.
Cevostamab Post-CAR T-Cell Therapy is Safe in Heavily Pretreated Multiple Myeloma
Adverse effects were manageable when patients with heavily pretreated multiple myeloma were given cevostamab consolidation after receiving CAR T-cell therapy.
Isa-KRd Yields Significant MRD Negativity in High-Risk NDMM Cytogenetic Subgroups
MRD-negative remission was achieved in 74.8% of all patients with newly diagnosed multiple myeloma treated with isatuximab, carfilzomib, lenalidomide, and dexamethasone.
Cevostamab Combo Shows Enduring Responses in R/R Multiple Myeloma
Additional time is necessary to confirm the depth and durability of responses observed in the phase 1 CAMMA 1 study.
Elranatamab Combo Yields Early Efficacy in Transplant-Ineligible NDMM
Responses observed with the elranatamab-based regimen in the MagnetisMM-6 trial are anticipated to deepen with longer follow-up.
Novel Allogenic CAR T Therapy Shows Responses in R/R Multiple Myeloma
P-BCMA-ALLO1 yielded lymphodepletion responses even among those with prior exposure to other CAR T-cell therapies or bispecific agents.
Post-Transplant Daratumumab Combo Increases MRD Negativity in NDMM
Data support the addition of daratumumab to standard lenalidomide maintenance in patients with newly diagnosed multiple myeloma following transplant.
Durcabtagene Autoleucel Yields Responses in Relapsed/Refractory Myeloma
Treatment with durcabtagene autoleucel meets the primary end point of a phase 2 study in relapsed/refractory multiple myeloma.
Novel BCL-2 Inhibitor Combo Shows Enduring Responses in R/R Myeloma Subtype
Data from a phase 1b/2 trial show that sonrotoclax/dexamethasone appears to be well tolerated in a heavily pretreated multiple myeloma population.
Isatuximab Combo Yields MRD-Negative Responses in Transplant-Eligible NDMM
Nearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.
Daratumumab Combo Yields MRD-Negative Status in Transplant-Ineligible NDMM
Phase 3 data support a daratumumab-based quadruplet as a new potential regimen in transplant-ineligible newly diagnosed multiple myeloma.
HDP-101 Demonstrates Preliminary Efficacy in R/R Multiple Myeloma
Investigators anticipate launching the dose-expansion portion of the phase 1 HDP-101-01 trial in 2025.
Talquetamab/Daratumumab Shows Durable Responses in R/R Multiple Myeloma
The combination of talquetamab plus daratumumab yields improved patient outcomes in those with relapsed/refractory multiple myeloma.
Talquetamab Combo Yields Enduring Responses in R/R Multiple Myeloma
Combining talquetamab with teclistamab elicits responses even among those with extramedullary disease in the RedirecTT-1 trial.
Daratumumab Regimens Improve Depth, Durability of MRD-Negativity Rates in Newly Diagnosed Multiple Myeloma
Extended follow-up from the CASSIOPEIA trial illustrates the PFS and MRD benefits of daratumumab-based induction/consolidation and maintenance therapy.
